Insights Into Boston Scientific (BSX) Q3: Wall Street Projections for Key Metrics

Wall Street analysts expect Boston Scientific (BSX) to post quarterly earnings of $0.76 per share in its upcoming report, which indicates a year-over-year increase of 1.3%. Revenues are expected to be $5.17 billion, up 2.1% from the year-ago quarter.

The consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.

That said, let's delve into the average estimates of some Boston Scientific metrics that Wall Street analysts commonly model and monitor.

Analysts predict that the 'Net Sales- MedSurg- Worldwide' will reach $1.75 billion. The estimate indicates a year-over-year change of +1.6%.

Analysts forecast 'Net Sales- Cardiovascular- Worldwide' to reach $3.32 billion. The estimate points to a change of -0.7% from the year-ago quarter.

The combined assessment of analysts suggests that 'Net Sales- MedSurg- Endoscopy- Worldwide' will likely reach $756.70 million. The estimate indicates a year-over-year change of +1.3%.

The consensus among analysts is that 'Net Sales- MedSurg- Neuromodulation- Worldwide' will reach $308.03 million. The estimate suggests a change of +5.1% year over year.

Analysts expect 'Net Sales- MedSurg- Urology- Worldwide' to come in at $667.93 million. The estimate indicates a change of -2.1% from the prior-year quarter.

The consensus estimate for 'Net Sales- Cardiovascular- Watchman- Worldwide' stands at $449.61 million. The estimate suggests a change of -12.2% year over year.

According to the collective judgment of analysts, 'Net Sales- Cardiovascular- Electrophysiology- Worldwide' should come in at $801.01 million. The estimate indicates a change of -7.4% from the prior-year quarter.

It is projected by analysts that the 'Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide' will reach $545.12 million. The estimate indicates a change of -5.7% from the prior-year quarter.

The average prediction of analysts places 'Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide' at $1.19 billion. The estimate indicates a year-over-year change of +73.5%.

The collective assessment of analysts points to an estimated 'Geographic Revenue- U.S.' of $3.22 billion. The estimate indicates a change of -2.3% from the prior-year quarter.

Analysts' assessment points toward 'Geographic Revenue- Rest of the World' reaching $1.84 billion. The estimate indicates a year-over-year change of +3.8%.

Shares of Boston Scientific have experienced a change of +3% in the past month compared to the -1.2% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), BSX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research